InsiderSignalSign in
← Insider buys

David P Bonita has bought stock on 9 days since Jul 2018

Director and 10% owner at Prelude Therapeutics Incorporated, and 9 other companies

SEC CIK 0001572451 · Filings on SEC.gov ↗

$67.4MBought
$138.5MSold
Apr 23Last buy

David P Bonita's record

3 months after each buy, from the first price a copier could get.

−47.0%Average
−51.9 ptsVs S&P 500
0 of 3Higher

3 buys since 2018 with 3 months of prices.

Companies

Every filing

20 filings since Aug 2016, newest first

PRLDBuy

Prelude Therapeutics Inc

Director and 10% owner

$12.5M−242.0%Apr 23
IMABuy

Imagenebio, Inc.

Director

$2.5M+12.0%Jul 30
TCDASell

Tricida, Inc.

Director and 10% owner

$2.2M−100.0%Nov 25
THRDBuy

Third Harmonic Bio, Inc.

Director and 10% owner

$5.1M+5.0%Sep 21
RPTXSell

Repare Therapeutics Inc.

Director

$275K−8.0%Sep 8
RPTXSell

Repare Therapeutics Inc.

Director

$1.3M−28.0%Sep 2
RPTXSell

Repare Therapeutics Inc.

Director

$616K−16.0%Aug 30
RPTXSell

Repare Therapeutics Inc.

Director

$693K−17.0%Aug 25
RPTXSell

Repare Therapeutics Inc.

Director

$622K−16.0%Aug 25
IKNABuy

Ikena Oncology, Inc.

Director

$6.8M−242.0%Apr 14
AFIBBuy

Acutus Medical, Inc.

Director and 10% owner

$7.5M+46.0%Aug 12
IMRABuy

Imara Inc.

Director and 10% owner

$15.0M+59.0%Mar 16
TCDASell

Tricida, Inc.

Director and 10% owner

$60.0M−13.0%Dec 12
TCDABuy

Tricida, Inc.

Director and 10% owner

$8.1M+2.0%Apr 5
SIBNBuy

Si-Bone, Inc.

Director

$3.0M+25.0%Oct 19
TCDABuy

Tricida, Inc.

Director and 10% owner

$7.0M+4.0%Jul 2
LOXOSell

Loxo Oncology, Inc.

Director

$20.6M−21.0%Dec 12
LOXOSell

Loxo Oncology, Inc.

Director

$20.0M−18.0%Nov 27
LOXOSell

Loxo Oncology, Inc.

Director

$20.1M−16.0%Nov 20
LOXOSell

Loxo Oncology, Inc.

Director

$12.1M−21.0%Aug 12
About David P Bonita

David P. Bonita, M.D. is a seasoned healthcare investor and board director, currently serving as an Independent Director at ImageneBio, Inc. (IMA) since 2025, alongside roles at Acutus Medical, Inc. (since 2016), Prelude Therapeutics, Inc. (since 2016), Repare Therapeutics, Inc. (since 2019), Third Harmonic Bio, Inc. (since 2020), and others, including as General Partner at OrbiMed Advisors Private Equity since 2020.(

Dr. Bonita previously held directorships at companies such as Tricida, Inc. (until 2023), SI-BONE, Inc. (2014-2019), and Loxo Oncology, Inc. (2013-2017), and began his career as a corporate finance analyst in healthcare investment banking at Morgan Stanley and UBS.( He holds an A.B. in Biological Sciences from Harvard University (1997) and joint M.D./M.B.A. degrees from Columbia University (2004).(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.